PMV Pharmaceuticals (PMVP) News Today $1.37 0.00 (0.00%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Barclays PLC Sells 434,704 Shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP)Barclays PLC decreased its stake in shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP - Free Report) by 93.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 30,248 shares of the company's stock after sellinJanuary 10, 2025 | marketbeat.comArrowMark Colorado Holdings LLC Acquires 842,509 Shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP)ArrowMark Colorado Holdings LLC increased its holdings in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP - Free Report) by 30.0% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,647,291 shares of the company's stock after acqDecember 3, 2024 | marketbeat.comPMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Given Average Rating of "Buy" by BrokeragesShares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP - Get Free Report) have been given an average recommendation of "Buy" by the six ratings firms that are presently covering the stock, Marketbeat reports. Five equities research analysts have rated the stock with a buy rating and one has issued a stDecember 3, 2024 | marketbeat.comSio Capital Management LLC Raises Holdings in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP)Sio Capital Management LLC increased its position in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP - Free Report) by 18.7% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,214,239 shares of the company'sNovember 29, 2024 | marketbeat.comPMV Pharmaceuticals files $200M mixed securities shelfNovember 22, 2024 | markets.businessinsider.comBML Capital Management LLC Grows Holdings in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP)BML Capital Management LLC lifted its holdings in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP - Free Report) by 29.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,688,772 shares of the company's stock after buying aNovember 12, 2024 | marketbeat.comPMV Pharmaceuticals upgraded to Outperform from Perform at OppenheimerNovember 9, 2024 | markets.businessinsider.comPMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Receives Average Rating of "Buy" from BrokeragesPMV Pharmaceuticals, Inc. (NASDAQ:PMVP - Get Free Report) has been assigned an average recommendation of "Buy" from the six research firms that are covering the stock, Marketbeat Ratings reports. Five analysts have rated the stock with a buy recommendation and one has given a strong buy recommendaNovember 8, 2024 | marketbeat.comPMV Pharmaceuticals (NASDAQ:PMVP) Raised to "Outperform" at OppenheimerOppenheimer upgraded shares of PMV Pharmaceuticals from a "market perform" rating to an "outperform" rating and set a $6.00 price target on the stock in a research report on Friday.November 8, 2024 | marketbeat.comPMV Pharmaceuticals Reports Third Quarter 2024 Financial ResultsNovember 7, 2024 | markets.businessinsider.comOppenheimer Sticks to Its Hold Rating for PMV Pharmaceuticals (PMVP)October 25, 2024 | markets.businessinsider.comPMV Pharmaceuticals (PMVP) Gets a Buy from Craig-HallumOctober 25, 2024 | markets.businessinsider.comPMV Pharmaceuticals Provides a Progress Update on PYNNACLE Clinical TrialOctober 23, 2024 | finance.yahoo.comPMV provides update on Phase 2, Phase 1b portions of PYNNACLE trialOctober 23, 2024 | markets.businessinsider.comPMV Pharma (NASDAQ:PMVP) Stock Quotes, Forecast and News SummaryOctober 8, 2024 | benzinga.comPenny Stocks To Buy With Just $1500: PMVP, BOLD, SPROSeptember 28, 2024 | msn.comPMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Insider Sells $10,827.00 in StockSeptember 13, 2024 | insidertrades.comInsider Selling: PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Insider Sells 7,218 Shares of StockPMV Pharmaceuticals, Inc. (NASDAQ:PMVP - Get Free Report) insider Deepika Jalota sold 7,218 shares of the business's stock in a transaction on Wednesday, September 11th. The stock was sold at an average price of $1.50, for a total transaction of $10,827.00. Following the completion of the sale, the insider now directly owns 118,283 shares of the company's stock, valued at $177,424.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.September 12, 2024 | marketbeat.comAssenagon Asset Management S.A. Boosts Holdings in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP)Assenagon Asset Management S.A. raised its holdings in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP - Free Report) by 267.2% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 260,028 shares of the company'sAugust 25, 2024 | marketbeat.comHC Wainwright Brokers Cut Earnings Estimates for PMV Pharmaceuticals, Inc. (NASDAQ:PMVP)PMV Pharmaceuticals, Inc. (NASDAQ:PMVP - Free Report) - Stock analysts at HC Wainwright dropped their Q3 2024 earnings estimates for shares of PMV Pharmaceuticals in a research note issued on Tuesday, August 20th. HC Wainwright analyst R. Burns now anticipates that the company will earn ($0.35) pAugust 22, 2024 | marketbeat.comPmv Pharmaceuticals Inc (PMVP)August 20, 2024 | investing.comPMV Pharmaceuticals (NASDAQ:PMVP) Given Buy Rating at HC WainwrightHC Wainwright restated a "buy" rating and issued a $5.00 target price on shares of PMV Pharmaceuticals in a research note on Tuesday.August 20, 2024 | marketbeat.comOppenheimer Reaffirms Their Hold Rating on PMV Pharmaceuticals (PMVP)August 9, 2024 | markets.businessinsider.comPMVP Stock Earnings: PMV Pharma Beats EPS for Q2 2024August 8, 2024 | markets.businessinsider.comPMV Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Progress Update on PYNNACLE Clinical TrialAugust 8, 2024 | finance.yahoo.comJacobs Levy Equity Management Inc. Purchases 397,062 Shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP)Jacobs Levy Equity Management Inc. lifted its position in shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP - Free Report) by 92.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 826,704 shares of the company's stockAugust 2, 2024 | marketbeat.comAcadian Asset Management LLC Increases Holdings in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP)Acadian Asset Management LLC raised its stake in shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP - Free Report) by 170.7% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,080,194 shares of the company's stock after buyJuly 24, 2024 | marketbeat.comFoundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C ReactivatorMay 29, 2024 | globenewswire.comFoundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C ReactivatorMay 29, 2024 | businesswire.comAnalysts Offer Insights on Healthcare Companies: PMV Pharmaceuticals (PMVP) and Phathom Pharmaceuticals (PHAT)May 17, 2024 | markets.businessinsider.comPMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Expected to Earn FY2025 Earnings of ($1.47) Per SharePMV Pharmaceuticals, Inc. (NASDAQ:PMVP - Free Report) - Equities researchers at HC Wainwright issued their FY2025 earnings per share estimates for PMV Pharmaceuticals in a report issued on Tuesday, May 14th. HC Wainwright analyst R. Burns anticipates that the company will post earnings of ($1.47)May 15, 2024 | marketbeat.comPMV Pharmaceuticals (NASDAQ:PMVP) Upgraded to "Strong-Buy" by CLSACLSA raised shares of PMV Pharmaceuticals to a "strong-buy" rating in a report on Monday.May 15, 2024 | marketbeat.comCraig-Hallum Initiates Coverage of PMV Pharmaceuticals (PMVP) with Buy RecommendationMay 14, 2024 | msn.comPMV Pharmaceuticals (NASDAQ:PMVP) Coverage Initiated at Craig HallumCraig Hallum initiated coverage on shares of PMV Pharmaceuticals in a report on Monday. They issued a "buy" rating and a $6.00 price target on the stock.May 13, 2024 | marketbeat.comPMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate HighlightsMay 9, 2024 | globenewswire.comPMV Pharmaceuticals (NASDAQ:PMVP) Is In A Good Position To Deliver On Growth PlansApril 19, 2024 | finance.yahoo.comPMV Pharmaceuticals (PMVP) Price Target Increased by 45.83% to 8.93April 18, 2024 | msn.comJefferies Financial Group Initiates Coverage on PMV Pharmaceuticals (NASDAQ:PMVP)Jefferies Financial Group initiated coverage on shares of PMV Pharmaceuticals in a report on Friday. They issued a "buy" rating and a $5.00 target price for the company.April 12, 2024 | marketbeat.comPMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid TumorsMarch 27, 2024 | globenewswire.comPMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women’s CancerMarch 18, 2024 | finance.yahoo.comPMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women's CancerMarch 18, 2024 | globenewswire.comPMVP Apr 2024 5.000 callMarch 16, 2024 | finance.yahoo.comHC Wainwright Research Analysts Lift Earnings Estimates for PMV Pharmaceuticals, Inc. (NASDAQ:PMVP)PMV Pharmaceuticals, Inc. (NASDAQ:PMVP - Free Report) - Equities research analysts at HC Wainwright lifted their Q1 2024 earnings per share (EPS) estimates for PMV Pharmaceuticals in a note issued to investors on Thursday, March 7th. HC Wainwright analyst R. Burns now anticipates that the companyMarch 11, 2024 | marketbeat.comRTW Investments LP Sells 653,766 Shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP)RTW Investments LP trimmed its stake in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP - Free Report) by 21.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,375,785 shares of the company's stock after sellingMarch 6, 2024 | marketbeat.comAlkeon Capital Management LLC Acquires 867,547 Shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP)Alkeon Capital Management LLC lifted its position in shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP - Free Report) by 58.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,347,414 shares of the company'March 3, 2024 | marketbeat.comPMV Pharmaceuticals, Inc.: PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate HighlightsMarch 3, 2024 | finanznachrichten.deOppenheimer Keeps Their Hold Rating on PMV Pharmaceuticals (PMVP)March 1, 2024 | markets.businessinsider.comPMV Pharmaceuticals Inc (PMVP) Reports Full Year 2023 Financial ResultsMarch 1, 2024 | finance.yahoo.comTD Cowen Reaffirms Their Buy Rating on PMV Pharmaceuticals (PMVP)March 1, 2024 | markets.businessinsider.comPMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate HighlightsFebruary 29, 2024 | globenewswire.com Get PMV Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PMVP and its competitors with MarketBeat's FREE daily newsletter. Email Address PMVP Media Mentions By Week PMVP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PMVP News Sentiment▼1.820.64▲Average Medical News Sentiment PMVP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PMVP Articles This Week▼01▲PMVP Articles Average Week Get PMV Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PMVP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies iTeos Therapeutics News Aquestive Therapeutics News Immutep News Neurogene News Olema Pharmaceuticals News Atyr PHARMA News Rezolute News Atea Pharmaceuticals News Compass Therapeutics News Canopy Growth News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PMVP) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredTrump Insider: Day One will Shock EveryoneA rare opportunity for everyday Americans like you to turn a small stake into real wealth in the stock market....InvestorPlace | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredInvesting Tools You’ll Need for 2025Investing Tools You’ll Need for 2025 Charles Payne Shares His #1 Strategy for 2025 Unstoppable Prosperity | SponsoredBitcoin to $200K?Newsweek recently asked several analysts whether they think Bitcoin will hit $200,000 by the end of 2025. T...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PMV Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PMV Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
